XML 126 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
EARNINGS (LOSS) PER SHARE
 12 Months Ended
Dec. 31, 2014
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc. for the years ended December 31, 2014, 2013 and 2012 were calculated as follows:
 
 
2014
 
2013
 
2012
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.
 
$
913.5

 
$
(866.1
)
 
$
(116.0
)
Basic weighted-average number of common shares outstanding
 
335.4

 
321.0

 
305.4

Dilutive effect of stock options and RSUs
 
6.1

 
—

 
—

Diluted weighted-average number of common shares outstanding
 
341.5

 
321.0

 
305.4

 
 
 
 
 
 
 
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
Basic
 
$
2.72

 
$
(2.70
)
 
$
(0.38
)
Diluted
 
$
2.67

 
$
(2.70
)
 
$
(0.38
)

In 2013 and 2012, all stock options, RSUs and convertible notes were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options, RSUs and convertible notes on the weighted-average number of common shares outstanding would have been as follows:
 
2013
 
2012
Basic weighted-average number of common shares outstanding
321.0

 
305.4

Dilutive effect of stock options and RSUs
6.5

 
7.2

Dilutive effect of convertible notes
—

 
0.5

Diluted weighted-average number of common shares outstanding
327.5

 
313.1


In 2014, 2013 and 2012, stock options to purchase approximately 877,000, 1,090,000 and 1,093,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.